Industry News

Natco Pharma Ltd's net profit rose 68% in the quarter ended 30 June, driven by sales growth of its domestic formulations business. The company posted a net profit of Rs.47 crore during the April-June quarter, compared with Rs.28 crore in the same period the previous year. Income from operations grew 45% to Rs.325.2 crore."/>
Natco Pharma Q1 profit rises 68% to Rs47 crore [Mint, New Delhi]
Lupin Ltd. Its sales in the June quarter rose by 40% over a year ago, which was expected as its US business has benefited from the sales of two major products, with US sales rising by 82%."/>
Lupin's margins trip on US business [Mint, New Delhi]
Jubilant Life Sciences Ltd on Tuesday posted a 22% rise in net profit for the quarter ended June on the back of improved performance of speciality pharmaceuticals and reduced expenses. Net profit rose to Rs.162 crore in the April-June period compared to Rs.132 crore in the year-ago quarter. Revenues declined 2% to Rs.1, 420 crore, the company said."/>
Jubilant Life Sciences profit up 22% to Rs162 crore in Q1 [Mint, New Delhi]
Lupin Ltd, India's third largest drug maker, reported a 55% growth in consolidated net profit for the quarter ended 30 June, beating analyst estimates on the back of improved US sales. Net profit rose to Rs.882 crore in April-June period from Rs.568.6 crore a year ago, Lupin said in a statement to BSE on Tuesday. Total revenues grew 41% to Rs.4, 439 crore, the company said."/>
Lupin posts record net profit of Rs882 crore in Q1 FY17 [Mint, New Delhi]
Mylan NV's allergic-reaction remedy EpiPen led a sales increase in the second quarter at the drugmaker as it leans heavily on specialty medications and acquisitions to offset pricing pressure in generic drugs. The Netherlands-based company, which is run from offices in Cecil, reported a 33 percent increase in sales in the April-June quarter from its specialty drug segment, which includes the popular EpiPen treatment for severe allergic reactions."/>
EpiPen helps boost Mylan's earnings [The Pittsburgh Tribune-Review]
Rite Aid. He and his insurance company paid the cost of his wife's medication during a recent visit."/>
Toms River man battles Rite Aid for refund [Asbury Park Press, N.J.]
Gannett Co., Inc. has closed its acquisition of the outstanding shares of US-based digital services provider ReachLocal, Inc. for USD 4.60 per share in cash, via a tender offer, the company said. The offer represents a 188% premium to the unaffected closing price on Friday,..."/>
M and A Navigator: Deal pipeline –10 August
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the pricing of an underwritten public offering of 6,060,606 shares of its common stock, offered at a price to the public of $33.00 per share. The gross proceeds from this offering to ACADIA are expected to be approximately $200.0 million, before..."/>
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
Connecture, Inc. concerning possible violations of federal securities laws. If you purchased or otherwise acquired Connecture shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us..."/>
INVESTOR NOTICE: Goldberg Law PC Announces an Investigation of Claims Against Connecture, Inc. and Advises Investors With Losses to Contact the Firm
Arrowhead Pharmaceuticals-- a California drug development company with most of its operations in Madison-- plans to raise $45 million in a private stock offering. Arrowhead said it is making 7.63 million shares of common stock available, at $5.90 a share, with Cantor Fitzgerald& Co. as the sole placement agent. The offering is expected to close by Aug. 12.."/>
Arrowhead Pharmaceuticals plans to raise $45 million [The Wisconsin State Journal]
Agilent Technologies Inc. today announced it has acquired 20 acres in Weld County, Colorado, on which it plans to build a pharmaceutical manufacturing facility. The expansion will enable the company to more than double its commercial manufacturing capacity for nucleic acid active pharmaceutical ingredients."/>
Agilent Technologies to Build New Facility in Colorado, Increasing Pharmaceutical Manufacturing Capacity
Cancer Genetics Continues to Increase Expected Future Revenue from Biopharma Contracts to over $47 Million Cancer Genetics to Host Conference Call Wednesday, August 10, 2016, at 8:30 AM Eastern Time/ 5:30 AM Pacific."/>
Cancer Genetics, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Updates
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that, further to its News Release of July 22, 2016, the TSX Venture Exchange has approved the consolidation of the common shares of the Company on the basis of ten pre-consolidation Shares for one post-consolidation Share. The Consolidation will become effective at the opening of the..."/>
RepliCel Life Sciences Share Consolidation Approved
Zoetis Inc. has completed the purchase of Denmark-based veterinary test services provider Scandinavian Micro Biodevices for USD 80 m, the company said. The acquisition adds to Zoetis' complementary point-of-care diagnostics portfolio, giving the company an expanded and promising pipeline in this fast-growing segment of the animal health industry. Privately-held-Scandinavian Micro Biodevices commercialized..."/>
Zoetis Acquires Scandinavian Veterinary Biodevices Provider for USD 80m
Cerner Corp., a health-care information technology company, will add 250 jobs in Malvern over the next three years with the help of a $1.25 million Pennsylvania First grant, Gov. As part of the deal, Cerner, based in Kansas City, Mo., will invest $75 million in the site and retain its 2,000 current employees. When Cerner bought the former Siemens Health Services in Feb. 2015 for $1.3 billion, Siemens Health had 2,800 employees in Pennsylvania, New Jersey, and Delaware attributed to..."/>
BRIEF: Cerner to add 250 jobs in Malvern [The Philadelphia Inquirer]
ProPhase Labs, Inc. today reported its net sales were $2.8 million for the three months ended June 30, 2016 as compared to net sales of $2.2 million for the three months ended June 30, 2015. The Company incurred a net loss for the three months ended June 30, 2016, of $1.1 million, or per share, compared to a net loss of $1.6 million, or per share, for the three months ended June 30, 2015.. The Company's sales are derived principally from its over-the-counter health..."/>
ProPhase Labs Reports Financial Results for the Three Months and Six Months Ended June 30, 2016; Exploring Strategic Alternatives to Enhance Shareholder Value
Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced its financial results and recent corporate highlights for the quarter ended June 30, 2016.. Lindsay A. Rosenwald, Chairman, President and CEO of Fortress, said,“ During the second quarter of 2016, we attained several milestones, including the commercialization of our first two..."/>
Fortress Biotech Reports Second Quarter 2016 Financial Results and Recent Corporate Highlights
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, today reported financial results for the second quarter ended June 30, 2016.. “In the second quarter we continued to advance our three ongoing Phase 3 trials, and we expanded our late-stage pipeline with the receipt of positive FDA guidance on our development plans for AXS-05 in Alzheimer’ s agitation,”..."/>
Axsome Therapeutics Reports Second Quarter 2016 Financial Results
Press Ganey stockholders concerning the proposed acquisition of the company by EQT Equity Fund EQT VII. The investigation concerns whether Press Ganey’ s board of directors failed to adequately shop the Company and obtain the best possible value for Press Ganey stockholders before entering into a definitive merger agreement with EQT. Under the terms of the agreement, Press Ganey stockholders..."/>
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Press Ganey Holdings, Inc. (PGND) on Behalf of Stockholders and Encourages Investors to Contact the Firm
UnitedHealth Group and $7.7 million in deferred loan funds from Minnesota Housing. MINNEAPOLIS---- Struggling military veterans will have access to new housing and resources to help end the cycle of..."/>
Construction Underway for New Affordable-Housing Community for Military Veterans Struggling with Homelessness
Immunovaccine Inc., a clinical-stage vaccine and immunotherapy company, today provided a corporate update and announced financial results for the second quarter ended June 30, 2016.. "In the second quarter of 2016," said Frederic Ors, Immunovaccine's Chief Executive Officer, "we continued to significantly build the three pillars that support the long-term success of Immunovaccine and our DepoVax™- based pipeline. Firstly, we continued to advance..."/>
Immunovaccine Provides Corporate Update and Announces Second Quarter 2016 Financial Results
Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company today announced its financial results for the quarter ended June 30, 2016.. Second Quarter Results and Balance Sheet Highlights. Our cash and cash equivalents were $4,891,313 at June 30, 2016, compared with $9,760,997 at March 31, 2016.."/>
Provectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary711 Articles
Information Technology675 Articles
Financials563 Articles
Health Care400 Articles
Industrials385 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at